Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Recognise the acute heart-failure phenotype, relieve congestion safely and escalate respiratory failure, shock or a reversible cardiac cause through the NICE route.
The first bedside decision is whether the patient is congested, hypoperfused, hypertensive or in shock. Pulmonary oedema with high BP needs rapid unloading and selected vasodilation; cold hypotensive failure needs cause-directed critical-care support rather than automatic escalation of diuretic or nitrate.
NICE makes IV diuresis the routine pharmacological treatment. Oxygen, NIV, nitrates and vasoactive drugs are conditional treatments tied to measured hypoxaemia, respiratory acidosis, severe hypertension/ischaemia or shock.
A new diagnosis needs echocardiography, usually within 48 hours, but immediate bedside imaging is required when shock, tamponade, severe valve disease or a mechanical post-MI complication is suspected.
Myocardial ischaemia or infarction can abruptly reduce ventricular contractility and compliance. It may also cause papillary-muscle dysfunction or another mechanical complication, rapidly increasing filling pressure and congestion.
A very rapid rhythm shortens filling and raises oxygen demand, while severe bradycardia reduces cardiac output. Either can precipitate pulmonary oedema or shock in a vulnerable heart.
Acute mitral or aortic valve failure, myocarditis, right-ventricular failure and mechanical post-infarction lesions can cause sudden haemodynamic deterioration, sometimes without preceding peripheral fluid accumulation.
Marked hypertension, infection, renal decline, anaemia, thyroid disease, treatment non-adherence and medicines that promote retention can upset a previously compensated circulation by increasing afterload, demand or intravascular volume.
Impaired contraction or relaxation, or acute valve dysfunction, can prevent the heart from handling venous return effectively. Filling pressures may rise upstream even when the ejection fraction is not known to be reduced.
Raised left-sided filling pressure increases pulmonary capillary hydrostatic pressure. Fluid first enters the interstitium and then the alveoli, reducing lung compliance and impairing oxygen transfer.
Oedematous lungs demand greater work of breathing and create ventilation–perfusion mismatch. Hypoxaemia, fatigue and acidaemia may follow, particularly when extensive alveolar flooding produces frothy sputum.
An abrupt afterload rise can shift blood into the pulmonary circulation without major total-body fluid gain. This explains flash pulmonary oedema with severe breathlessness but little peripheral oedema.
When forward flow falls, cerebral, renal and peripheral perfusion deteriorate. Cool skin, confusion, oliguria and rising lactate signal progression from congestion towards cardiogenic shock.
Acute severe dyspnoea, orthopnoea, diffuse crackles, hypoxaemia and sometimes pink frothy sputum; marked work of breathing or acidaemia signals imminent ventilatory failure.
Raised JVP, peripheral oedema, ascites, weight gain and pulmonary congestion with maintained BP/perfusion; IV diuresis is central.
Abrupt pulmonary oedema with markedly elevated BP may reflect afterload-driven fluid redistribution rather than massive total-body fluid excess.
Hypotension with cool peripheries, confusion, oliguria and rising lactate; rapidly assess ACS, mechanical disease, RV failure and arrhythmia.
ACS, rapid/slow arrhythmia, acute valve lesion, myocarditis, PE, infection, anaemia, thyroid disease, non-adherence, NSAIDs or renal decline may be the treatable driver.
Prominent wheeze, prolonged expiration and an obstructive respiratory history favour airways disease. Raised venous pressure, pulmonary congestion and relevant cardiac or natriuretic-peptide findings support heart failure, although both conditions can coexist.
Fever, focal bronchial breathing, inflammatory markers and lobar consolidation favour infection. Cardiogenic oedema is usually more diffuse, but asymmetric oedema can resemble pneumonia and infection may precipitate heart failure.
Pleuritic pain, haemoptysis, venous thromboembolic risk and disproportionate hypoxaemia suggest pulmonary embolism. Right-heart strain without typical left-sided congestion strengthens that alternative diagnosis.
A clear systemic insult, inflammatory shock and bilateral infiltrates without dominant cardiac filling-pressure features support non-cardiogenic pulmonary oedema. Echocardiography and the overall haemodynamic pattern help separate or identify coexistence.
Advanced renal dysfunction, reduced urine output and widespread volume accumulation may drive pulmonary congestion without primary cardiac deterioration. Renal and cardiac causes frequently overlap, so echocardiography and serial assessment are useful.
COPD/asthma, pneumonia, PE, ARDS, renal fluid overload and sepsis can mimic or coexist; natriuretic peptides and imaging support but do not replace clinical integration.
Progressive alveolar flooding causes severe hypoxaemia, respiratory muscle fatigue and acidaemia. Non-invasive or invasive ventilatory support may be needed when work of breathing remains high despite initial treatment.
Inadequate forward flow produces hypotension and tissue hypoperfusion, with confusion, cool peripheries, oliguria and rising lactate. This phenotype requires urgent cause-directed cardiac and critical-care support.
Reduced renal perfusion and venous congestion can impair filtration, while diuresis alters fluid and electrolyte balance. Trends should be interpreted alongside congestion, perfusion and response to treatment rather than as isolated laboratory values.
Raised wall stress, hypoxaemia and sympathetic activation increase myocardial oxygen demand and electrical instability. Ischaemia or a malignant rhythm can then worsen ventricular function and create a self-perpetuating decline.
Residual pulmonary or systemic congestion after apparent improvement increases the likelihood of early deterioration and readmission. Discharge planning should confirm clinical stability, a working aetiology and precipitant plan, and specialist follow-up.
A hypertensive wet patient and a cold hypotensive patient can look equally breathless but need very different haemodynamic treatment.
NICE reserves immediate NIV for severe dyspnoea with acidaemia in cardiogenic pulmonary oedema, or failure of medical therapy—not routine use in every congested patient.
A modest creatinine rise during successful decongestion may not mean treatment failure; persistent congestion itself worsens renal function and outcome.
Acute MR, ischaemia or marked afterload may cause severe pulmonary oedema without large peripheral oedema or weight gain.
Residual congestion and an untested follow-up plan predict readmission; stability, education, medicines and early specialist review must be explicit.
Giving oxygen to every patient regardless of saturation.
Using nitrates, morphine or NIV routinely instead of tying them to a defined indication.
Giving the same low IV furosemide dose to a patient already taking high-dose oral loop diuretic.
Stopping decongestion solely for a small creatinine change without reassessing congestion and perfusion.
Missing ACS, acute MR or another reversible cause by labelling the episode simply 'fluid overload'.
Your practice draft is saved in this browser.
A patient admitted with acute congestive heart failure already takes furosemide 80 mg orally each morning. Which initial diuretic principle best matches NICE guidance?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Monitor BP, urine output, creatinine, sodium, potassium and magnesium. Give IV furosemide slowly—this SmPC limits injection to 4 mg/min, or 2.5 mg/min in advanced renal failure (serum creatinine above 442 micromol/L); rapid/high dosing increases hypotension, electrolyte-loss and ototoxicity risk.
Avoid in hypotension, RV infarction/preload dependence or recent PDE5-inhibitor use; severe aortic stenosis requires specialist haemodynamic judgement. Continuous BP monitoring is required.
For this cited product use a central venous catheter and preferably arterial BP monitoring; other preparations have different concentrations and labels. Watch for arrhythmia, ischaemia and extravasation, and correct the cause concurrently.
Tachyarrhythmia, myocardial ischaemia and hypotension; ICU/cardiology supervision only and use the lowest effective duration.